logo
ProjectEnded

Engineering and Delivering B Cells Using Biomaterials against Breast Cancer

Ended · Germany

Source: EU Funding & Tenders Portal

Breast cancer (BC) is the most diagnosed cancer worldwide, and despite treatment availability, the disease remains challenging to treat, causing substantial adverse side effects and fatalities globally. The lack of efficacy and inaccessibility of standard care supports this demand for better treatments. This is demonstrated by resection surgery and current (neo)adjuvant therapies such as chemother

Status
Closed
Sector
Commercial, Government, Automotive
Location
Germany
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Engineering and Delivering B Cells Using Biomaterials against Breast Cancer

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “Engineering and Delivering B Cells Using Biomaterials against Breast Cancer” is an infrastructure initiative in the Commercial sector, located in Germany. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Sponsoring Agency

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Breast cancer (BC) is the most diagnosed cancer worldwide, and despite treatment availability, the disease remains challenging to treat, causing substantial adverse side effects and fatalities globally. The lack of efficacy and inaccessibility of standard care supports this demand for better treatments. This is demonstrated by resection surgery and current (neo)adjuvant therapies such as chemotherapy exhibiting inadequacies resulting in 30% of BC patients having metastases. These percentages are even higher in low human index regions due to inaccessibility, cost and growing populations. Adoptive cell therapy (ACT), such as CAR-T, is a category of emerging immunotherapies expected to impact oncology by transferring engineered immune cells into a patient to eliminate cancer cells. However, these treatments are currently ineffective in BC and costly. END-BC will complement research into B cells to produce an ACT that improves treatment efficacy against breast cancer while reducing side effects and costs from effective therapy. Our research developed novel biomaterial to overcome significant obstacles to successfully enhance B cell functions against cancer using a low-cost method. In END-BC, we will research the commercial and technical feasibility of tailoring the B cell ACT with biomaterials to determine its potential to treat BC.

Location

Country

Germany

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Commercial, Government, Automotive

Article published date

2026-02-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project